4 April 2022

Congratulations to Par Equity portfolio company Axol Bioscience Ltd. on recently completing a £3.2m fundraise to drive commercialisation of additional human induced pluripotent stemcell (iPSC) products and service solutions for cardiac, neuroscience and immune cell modelling for the drug discovery and screening markets. 

The funds will enable Axol to optimize further cell culture quality and iPSC manufacturing capabilities at its site in the Roslin Institute in Edinburgh, UK, as well as to support recruitment efforts to expand its commercial team. 
Other investors participating in the round alongside Par Equity included Calculus Capital and Scottish Enterprise, with support from Meltwind Advisory LLP, including early investor Dr Jonathan Milner.